Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -2.08%33 1-Year ROIIC % is -629.24 as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,341 Biotechnology companies, Island Pharmaceuticals ranks worse than 87.77% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Island Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Dec. 2025 was -629.24%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Island Pharmaceuticals's 1-Year ROIIC % or its related term are showing as below:
ASX:ILA's 1-Year ROIIC % is ranked worse than 87.77% of 1341
companies
in the Biotechnology industry
Industry Median: -8.77
vs ASX:ILA: -629.24
Island Pharmaceuticals (ASX:ILA) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Island Pharmaceuticals 1-Year ROIIC % Related Terms
Island Pharmaceuticals 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Island Pharmaceuticals's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ILA vs VRTX, REGN, ALNY: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's 1-Year ROIIC % falls into.
Island Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -7.317 (Dec. 2025) - -2.346 (Dec. 2024) )
/
( 0.825 (Dec. 2025) - 0.035 (Dec. 2024) )
=
-4.971
/
0.79
=
-629.24%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Island Pharmaceuticals (ASX:ILA) has a 1-Year ROIIC % of -629.24 as of Dec. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #1177 out of 1341 companies in the Biotechnology industry, placing it in the top 87.8%.
Is Island Pharmaceuticals' 1-Year ROIIC % too high?
Island Pharmaceuticals' current 1-Year ROIIC % is -629.24. Based on the distribution chart, Island Pharmaceuticals ranks #1177 out of 1341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' 1-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #1177 out of 1341 companies for 1-Year ROIIC %. This places Island Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current 1-Year ROIIC % is -629.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current 1-Year ROIIC % of -629.24. The current 1-Year ROIIC % is -629.24. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current 1-Year ROIIC % is -629.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score
Get the complete analysis for ASX:ILA
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
